Intervention

Cannabidiol

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 21 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting3
Common conditions22
Lead sponsors shown15
Advertisement

Clinical trials

21 shown
Cannabidiol for Pain Relief of Patients With End-stage mCRPCNCT07549256 · 2026-06-12
RECRUITING
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer SurvivorsNCT06731894 · 2025-10-03
RECRUITING
CBD for Individuals at Risk for Alzheimer's DiseaseNCT05822362 · 2024-01-19
RECRUITING
Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer SurvivorsNCT05672342 · 2024-07-06
WITHDRAWN
Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid ArthritisNCT05942911 · 2023-11-22
TERMINATED
Oral Cannabidiol Effect on Blood Pressure in Hypertensive PatientsNCT05346562 · 2022-04-08
COMPLETED
RCT of CBD for Anxiety in Advanced Breast CancerNCT04482244 · 2022-01-19
ACTIVE_NOT_RECRUITING
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.NCT05016349 · 2021-08-01
UNKNOWN
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionNCT05044819 · 2021-07-07
ACTIVE_NOT_RECRUITING
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis UseNCT04105231 · 2021-06-01
ACTIVE_NOT_RECRUITING
Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-CNCT03634189 · 2021-03-01
UNKNOWN
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental StudyNCT04605393 · 2021-01-01
COMPLETED
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's DiseaseNCT03582137 · 2018-09-05
COMPLETED
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi SyndromeNCT02844933 · 2018-05-09
TERMINATED
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of SchizophreniaNCT02932605 · 2017-11-03
COMPLETED
Cannabidiol Treatment in Patients With Early PsychosisNCT02504151 · 2016-01-28
COMPLETED
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic PatientsNCT02088060 · 2015-12-08
TERMINATED
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction StudyNCT02051387 · 2013-01-01
COMPLETED
The Effects of Cannabidiol and ∆-9-THC in HumansNCT01180374 · 2010-02-01
COMPLETED
Cannabidiol Treatment of Cognitive Dysfunction in SchizophreniaNCT00588731 · 2009-02-01
COMPLETED
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic PsychosisNCT00628290 · 2002-10-01
COMPLETED

Trial status mix

COMPLETED9
ACTIVE_NOT_RECRUITING3
RECRUITING3
TERMINATED3
UNKNOWN2
WITHDRAWN1

Phase mix

PHASE212
PHASE13
EARLY_PHASE12
NA2
PHASE31
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.